
    
      This study is a randomized, double-blind, multi-center, sham-controlled clinical trial. In
      this trial, 118 subjects will be enrolled. Subjects with signed informed consent are screened
      and assigned randomly (1:1) to one of the following parallel groups: Group A-Intravitreous
      0.5 mg ranibizumab injections and Group B-sham injections. All participants have visits at 0
      month, 1 month, and 2 months, followed by visits every 3 months thereafter through 1 year.
      The main efficacy and safety outcomes assessment will be finished at the end of 12 months.
    
  